Kirk E. Guyer

2.2k total citations · 1 hit paper
24 papers, 1.7k citations indexed

About

Kirk E. Guyer is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pharmacology. According to data from OpenAlex, Kirk E. Guyer has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 12 papers in Surgery and 4 papers in Pharmacology. Recurrent topics in Kirk E. Guyer's work include Antiplatelet Therapy and Cardiovascular Diseases (15 papers), Lipoproteins and Cardiovascular Health (6 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Kirk E. Guyer is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (15 papers), Lipoproteins and Cardiovascular Health (6 papers) and Atrial Fibrillation Management and Outcomes (5 papers). Kirk E. Guyer collaborates with scholars based in United States, Japan and Mexico. Kirk E. Guyer's co-authors include Paul A. Gurbel, David G.M. Carville, Wei C. Lau, Paul B. Watkins, Eric Bates, Alan R. Tait, Udaya S. Tantry, Kevin P. Bliden, Rolf P. Kreutz and Lucy Waskell and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Kirk E. Guyer

23 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platelet Reactivity in Patients and Recurrent Events Post-Stenting

2005 531 citations Paul A. Gurbel, Kevin P. Bliden et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kirk E. Guyer United States	12	1.5k	798	520	283	198	24	1.7k
Mark J. Antonino United States	17	2.2k 1.5×	1.0k 1.3×	855 1.6×	269 1.0×	286 1.4×	37	2.4k
Christian M. Hackeng Netherlands	17	1.7k 1.2×	783 1.0×	476 0.9×	261 0.9×	307 1.6×	40	2.0k
Joseph DiChiara United States	13	1.3k 0.9×	571 0.7×	508 1.0×	287 1.0×	192 1.0×	19	1.5k
Nicoline J. Breet Netherlands	18	1.7k 1.2×	831 1.0×	536 1.0×	234 0.8×	283 1.4×	28	1.8k
Heleen Bouman Netherlands	19	1.9k 1.3×	899 1.1×	569 1.1×	377 1.3×	453 2.3×	31	2.2k
Ankie M. Harmsze Netherlands	14	1.2k 0.8×	574 0.7×	375 0.7×	196 0.7×	257 1.3×	30	1.4k
Tanja Morath Germany	19	2.3k 1.6×	1.1k 1.4×	638 1.2×	403 1.4×	474 2.4×	30	2.6k
Fabiana Rollini United States	29	2.2k 1.5×	1.1k 1.4×	602 1.2×	142 0.5×	315 1.6×	112	2.5k
Rolf P. Kreutz United States	16	984 0.7×	482 0.6×	403 0.8×	132 0.5×	132 0.7×	54	1.4k
Delphine Brugier France	13	1.1k 0.7×	570 0.7×	317 0.6×	186 0.7×	250 1.3×	35	1.5k

Countries citing papers authored by Kirk E. Guyer

Since Specialization

Citations

This map shows the geographic impact of Kirk E. Guyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk E. Guyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk E. Guyer more than expected).

Fields of papers citing papers by Kirk E. Guyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk E. Guyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk E. Guyer. The network helps show where Kirk E. Guyer may publish in the future.

Co-authorship network of co-authors of Kirk E. Guyer

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk E. Guyer. A scholar is included among the top collaborators of Kirk E. Guyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk E. Guyer. Kirk E. Guyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raynard, Steven, et al.. (2024). An aptamer-based point-of-care diagnostic test strip for rapid diagnosis of surface spike proteins of SARS-CoV2 virus. SHILAP Revista de lepidopterología. 1(3). 199–204. 1 indexed citations

Bliden, Kevin P., Rahul Chaudhary, Luis R. Lopez, et al.. (2016). Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. The American Journal of Cardiology. 118(5). 673–678. 7 indexed citations

Bliden, Kevin P., Martin G. Gesheff, Kirk E. Guyer, et al.. (2015). Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy. The American Journal of Cardiology. 115(9). 1204–1211. 19 indexed citations

Lopez, Luis R., Kirk E. Guyer, Ignacio Garcı́a-De La Torre, et al.. (2014). Platelet thromboxane (11-dehydro-Thromboxane B₂) and aspirin response in patients with diabetes and coronary artery disease. World Journal of Diabetes. 5(2). 115–115. 38 indexed citations

Bliden, Kevin P., Anand Singla, Peter P. Tóth, et al.. (2014). Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. Thrombosis and Haemostasis. 112(8). 323–331. 10 indexed citations

Varnell, Charles D., Stuart L. Goldstein, Donald L. Yee, et al.. (2014). Age‐related differences in urinary 11‐dehydroxythromboxane B2 between infants, children, and adolescents: Another example of developmental hemostasis?. Pediatric Blood & Cancer. 61(11). 2074–2076. 4 indexed citations

Singla, Anand, Kevin P. Bliden, Udaya S. Tantry, et al.. (2012). Abstract 15997: First Report of a Dose Dependent Effect of Statin Therapy on Urinary 11-dehydrothromboxane Br2 rLevels: A New Marker for Personalizing Statin Therapy. Circulation. 126. 1 indexed citations

Ames, Paul R. J., Joana R. Batuca, Ivana J Muncy, et al.. (2012). Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. Thrombosis Research. 130(3). 350–354. 27 indexed citations

Walsh, Mark, Scott Thomas, E.P. Evans, et al.. (2011). Blood Component Therapy in Trauma Guided with the Utilization of the Perfusionist and Thromboelastography. Journal of ExtraCorporeal Technology. 43(3). 162–167. 29 indexed citations

10.

Walsh, Mark, Scott Thomas, E.P. Evans, et al.. (2011). Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography.. PubMed. 43(3). 162–7. 25 indexed citations

11.

Geske, F. Jon, Kirk E. Guyer, & Gordon Ens. (2008). Aspirin Works®. Molecular Diagnosis & Therapy. 12(1). 51–54. 8 indexed citations

12.

Guyer, Kirk E., et al.. (2007). Point-of-Care Monitoring for Optimal Antiplatelet Therapy in Acute Clinical Settings. Point of Care The Journal of Near-Patient Testing & Technology. 6(3). 208–212. 3 indexed citations

13.

Gurbel, Paul A., et al.. (2006). Delayed thrombin-induced platelet–fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thrombosis Research. 119(5). 563–570. 39 indexed citations

14.

Gurbel, Paul A., et al.. (2005). Platelet Reactivity in Patients and Recurrent Events Post-Stenting. Journal of the American College of Cardiology. 46(10). 1820–1826. 531 indexed citations breakdown →

15.

Lau, Wei C., Paul A. Gurbel, Paul B. Watkins, et al.. (2004). Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance. Circulation. 109(2). 166–171. 362 indexed citations

16.

Lau, Wei C., et al.. (2003). Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing. Journal of the American College of Cardiology. 41(6). 225–226. 4 indexed citations

17.

Lau, Wei C., Lucy Waskell, Paul B. Watkins, et al.. (2002). The effect of drugs which are known inducers and inhibitors of human cytochrome P450 3A on the platelet inhibitory activity of clopidogrel. Journal of the American College of Cardiology. 39. 235–235. 2 indexed citations

18.

Lakkis, Nasser, et al.. (2001). Use of ICHOR‐platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Catheterization and Cardiovascular Interventions. 53(3). 346–351. 25 indexed citations

19.

Carville, David G.M., et al.. (1998). Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer.. PubMed. 30(4). 171–7. 28 indexed citations

20.

Carville, David G.M., et al.. (1998). Whole Blood Platelet function Assay on the /CHOR^TM Point-of-Care Hematology Analyzer. Journal of ExtraCorporeal Technology. 30(4). 171–177. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact